BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has chosen it to supply biosamples for the Neurofilament as a Blood-Based Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD) Project.